Our primary aim in this project was to compare the impact of APOE4 on mortality risk for two competing types of deaths: death with low amounts of AD neuropathology versus death with high amounts of AD neuropathology, and to discuss potential preventive measures for developing high amounts of neuropathology among APOE4 carriers. Here, APOE is linked to Alzheimer disease.